Evidence map›Paper›PMID 31033233›Full record

ArticleCancer medicine2019

Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq.

Qianqian Song, Gregory A Hawkins, Leonard Wudel, Ping-Chieh Chou, Elizabeth Forbes, Ashok K Pullikuth, Liang Liu, Guangxu Jin, Lou Craddock, Umit Topaloglu and 10 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 174 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Qianqian SongCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Gregory A HawkinsCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Leonard WudelDepartment of Surgery, Wake Forest School of Medicine, Winston Salem, North Carolina.
Ping-Chieh ChouCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Elizabeth ForbesCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Ashok K PullikuthCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Liang LiuCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Guangxu JinCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Lou CraddockCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Umit TopalogluCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Gregory KuceraCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Stacey O'NeillCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Edward A LevineCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Peiqing SunDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Kounosuke WatabeDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Yong LuDepartment of Immunology and Microbiology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Martha A Alexander-MillerDepartment of Immunology and Microbiology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Boris PascheCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Lance D MillerCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Wei ZhangCenter for Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.ORCID 0000-0002-2235-1851
Atrium Health Wake Forest Baptist · USWake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Tip60 in p38 and PRAK Mediated Oncogene-Induced Senescence and Tumor SuppressionR01CA131231 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUN, PEIQING · 2009 to 2018
$3.5M
The role of microRNA in oncogene-induced senescence and cancer developmentR01CA172115 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUN, PEIQING · 2014 to 2018
$1.8M
NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA131231NCI NIH HHS R01 CA172115
6 · The paper itself

Abstract

Tumor-infiltrating myeloid cells are the most abundant leukocyte population within tumors. Molecular cues from the tumor microenvironment promote the differentiation of immature myeloid cells toward an immunosuppressive phenotype. However, the in situ dynamics of the transcriptional reprogramming underlying this process are poorly understood. Therefore, we applied single cell RNA-seq (scRNA-seq) to computationally investigate the cellular composition and transcriptional dynamics of tumor and adjacent normal tissues from 4 early-stage non-small cell lung cancer (NSCLC) patients. Our scRNA-seq analyses identified 11 485 cells that varied in identity and gene expression traits between normal and tumor tissues. Among these, myeloid cell populations exhibited the most diverse changes between tumor and normal tissues, consistent with tumor-mediated reprogramming. Through trajectory analysis, we identified a differentiation path from CD14+ monocytes to M2 macrophages (monocyte-to-M2). This differentiation path was reproducible across patients, accompanied by increased expression of genes (eg, MRC1/CD206, MSR1/CD204, PPARG, TREM2) with significantly enriched functions (Oxidative phosphorylation and P53 pathway) and decreased expression of genes (eg, CXCL2, IL1B) with significantly enriched functions (TNF-α signaling via NF-κB and inflammatory response). Our analysis further identified a co-regulatory network implicating upstream transcription factors (JUN, NFKBIA) in monocyte-to-M2 differentiation, and activated ligand-receptor interactions (eg, SFTPA1-TLR2, ICAM1-ITGAM) suggesting intratumoral mechanisms whereby epithelial cells stimulate monocyte-to-M2 differentiation. Overall, our study identified the prevalent monocyte-to-M2 differentiation in NSCLC, accompanied by an intricate transcriptional reprogramming mediated by specific transcriptional activators and intercellular crosstalk involving ligand-receptor interactions.

Indexed as

Cell PlasticityHumansMyeloid CellsRNA-SeqSignal TransductionTumor Microenvironmentintercellular interactionmonocyte-to-M2 differentiationnon-small cell lung cancer (NSCLC)single-cell RNA sequencing (scRNA-seq)trajectory analysis

Identifiers

PMID31033233
PMCPMC6558497
OpenAlexW2943598479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.